Section 17 · Monograph
Vibegron
Reviewed Nov 2026FDA label
GemtesaBeta-3 agonist
- Forms
- Tab: 75mg
- Dose
- 75mg once daily with or without food
- MOA
- Selective beta-3 adrenergic agonism, ↑bladder capacity
Indications
- Overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequency in adultsFDA-labeled
Mechanism of Action
- Selective beta-3 adrenergic receptor agonist that relaxes detrusor smooth muscle during filling, increasing bladder capacity
Full Dosing
Adult / usual
- 75mg once daily with or without food
- Swallow whole with water or crush and mix with about 15mL applesauce and take immediately
Renal
- Not recommended in severe renal impairment; no adjustment for mild to moderate renal or hepatic impairment
Contraindications
- Known hypersensitivity to vibegron or its components
Drug Interactions
- Digoxin levels may increase — monitor
Adverse Effects
- Headache, nasopharyngitis, urinary tract infection, nausea, diarrhea
- Urinary retention
- Minimal effect on blood pressure compared with other agents (monitor)
Monitoring Parameters
- Post-void residual in neurogenic bladder
- Blood pressure periodically
Pregnancy & Lactation
- Limited data; use only if benefit justifies risk
- Unknown whether present in human milk